Collectively, these results suggest that not only NRP1, but also HIF-1α, could be potential targets to hinder an autophagy-associated response by HCC cells as part of a hypoxia-derived adaptation that promote the loss of lenvatinib effectiveness. Here, HIF1A is linked to hepatocellular carcinoma.